Integrating MCP-1 assessment into routine diagnostics could sharpen the identification of high-risk patients and aid in optimizing therapeutic strategies, especially in those with obesity and hypertension. Here, CCL2 is linked to obesity due to melanocortin 4 receptor deficiency.